Lenz & Staehelin on the IPO of NLS Pharmaceutics 

NLS Pharmaceutics priced a USD 20 million IPO of 4,819,277 units consisting of one common share and one warrant to purchase one common share which are immediately separable from the units and issued separately.

The common shares and the warrants have been approved for listing on the Nasdaq Capital Market under the symbols “NLSP” and “NLSPW”, respectively, and trading began on January 29, 2021. The offering closed on February 2, 2021.

The team
Lenz & Staehelin acted as Swiss counsel to the underwriters. The team included Patrick Schleiffer, Patrick Schärli and Ann Francesca Weibel (all Corporate and Capital Markets).


Headquarted in Stans, Switzerland, NLS Pharmaceutics is a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders.

Lenz & Staehelin on the IPO of NLS Pharmaceutics 



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram